Platinum compounds-taxanes pharmacologic interactions;Pharmacologie des interactions derives du platine-taxanes

Bulletin du Cancer

Volumn 87, Issue SPEC. ISS. AUG., 2000, Pages 30-33

  Boisdron Celle, M ^a   Gamelin, E ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Interactions; Platinum derivatives; Taxoids

Indexed keywords

CISPLATIN; DOCETAXEL; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; CARBOPLATIN;

DNA ADDUCT; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG EFFICACY; DRUG METABOLISM; DRUG MIXTURE; DRUG TOLERABILITY; HUMAN; NEUTROPENIA; PHARMACODYNAMICS; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA; AREA UNDER THE CURVE; CHEMICALLY INDUCED DISORDER; DRUG INTERACTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CISPLATIN; DRUG INTERACTIONS; HUMANS; NEUTROPENIA; PACLITAXEL; THROMBOCYTOPENIA;

EID: 0033811101     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Sequence-dependent cytotoxicity between cisplatin and the antimicrotubule agents taxol and vincristine
2. Sequences of taxol and cisplatin: A phase I and pharmacologic study
3. Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the gynecologic Oncology Group
4. Evaluation of carboplatin pharmacokinetics on the absence and presence of paclitaxel
5. Pharmacokinetics of paclitaxel and carboplatin in a dose escalating and dose sequencing study in patients with non-small-cell lung cancer
6. Reduced platelet toxicity with combination carboplatin and paclitaxel: Pharmacodynamic modulation of carboplatin associated thrombocytopenia
7. Relationship between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer
8. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
9. Clinical development of platinum complexes in cancer therapy: An historitical perspective and an update
10. Comparative clinical pharmacology of cisplatin and carboplatin
11. Metabolism of taxol by human and rat liver in vitro: A screen for drug interactions and interspecies differences
12. Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4
13. Drug interactions with the taxanes
14. Considerations regarding the less-than-expected thrombocytopenia encountered with combination paclitaxel/carboplatin chemotherapy
15. Saturable pharmacokinetics and paclitaxel phatmacodynamics in children with solid tumors
16. Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors
17. Clinical pharmacology of carboplatin administered in combination with paclitaxel
18. Metabolism of docetaxel by human cytochrom P450: Interactions with paclitaxel and other antineoplastic drugs
19. Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes
20. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer
21. Decreased phenytoin level after carboplatin treatment
22. Platinum anticancer drugs modulate P-450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats
23. Extensive and saturable accumulation of paclitaxel by the human platelet
24. Taxol induces the hematopoietic growth factor granulocyte-macrophage colony-stimulating factor in murine B-cells by stabilization of granulocyte-macrophage colony-stimulating factor nuclear RNA